WXXWY:OTCMKTS
Wuxi Biologics Cayman ADR
US$ 12,56
arrow_upward
+0,48%(+0,060) 1D
16 de out., 16:00:00 GMT-4 · USD
search
Todos os ativos
| Códigos | Preço | Variação | % de variação |
|---|
insights_autoGerando os principais insights para WXXWY…
Abrir
US$ 12,29
Alta
US$ 12,56
Baixa
US$ 12,20
Valor de mercado
198,43 bi
Volume médio
61,89 mil
Volume
110,85 mil
Alto — 52 sem
US$ 14,80
Baixo — 52 sem
US$ 7,30
Beta
0,01
Ações em circulação
2,06 bi
Nº de funcionários
15 mil
Abrir
US$ 12,29
Alta
US$ 12,56
Baixa
US$ 12,20
Valor de mercado
198,43 bi
Volume médio
61,89 mil
Volume
110,85 mil
Alto — 52 sem
US$ 14,80
Baixo — 52 sem
US$ 7,30
Beta
0,01
Ações em circulação
2,06 bi
Nº de funcionários
15 mil
Notícias
De fontes da web e parceiros de notícias
Vietnam.vn
·
há 2 dias
Resumo Rápido 16-10: Dow Jones sobe mais de 550 pontos com queda nos rendimentos dos títulos; PV Power estima lucro de mais de 5,4 trilhões de VND nos primeiros nove meses
Times Brasil | CNBC
·
há 2 dias
Dow Jones dispara mais de 500 pontos com investidores reduzindo exposição a ações ligadas à IA
Benzinga
·
há 14 minutos
Dow Jones, Nasdaq 100, S&P 500 Outlook: Top Catalysts to Move US Stocks This Week
Simply Wall Street
·
há 23 minutos
Did FDA Filings Just Shift Cogent Biosciences Stock Investment Narrative?
Perfil
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Sobre Wuxi Biologics Cayman ADR